Agenus shares rise 10.20% intraday after reporting strong Q4 results and advancing BOT+BAL immunotherapy with global access and 42% survival rate in colorectal cancer trials.

Agenus surged 10.20% intraday, reporting Q4 2025 earnings of $0.56 per share (vs. expected loss of $1.27) and revenue of $34.2 million (17.54% above expectations). The company highlighted significant progress in its BOT+BAL immunotherapy, including a 42% two-year survival rate in colorectal cancer patients, a $4.2 million initial revenue milestone, and global early access program expansion across 30+ countries with over 200 physician inquiries.